In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis
Authors:
- 30 October 2019
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (2) , 145-154
Abstract
Psoriasis is a multifactorial skin disease involving abnormal cell proliferation and inflammation; an efficacious topical treatment is yet to be identified. A formulation containing 1% Naltrexone HCl in XemaTop™ base was compounded, characterized and evaluated in vitro as a possible treatment for psoriasis. A three-dimensional psoriasis tissue model was exposed to the formulation for 2 or 5 days and analyzed for the level of markers of cellular proliferation, and inflammatory cytokine IL-6. Using immunohistochemical staining, the level of Ki67 protein significantly decreased in the drug-treated tissues. Western blot analysis showed 86% and 53% down-regulation of other proliferation markers PCNA and CYCLIN D1, respectively, after 5-day exposure. The pro-survival Wnt/β-catenin pathway was compromised as indicated by 57% decrease in the level of β-CATENIN and down-regulation of its down-stream targets including CYCLIN D1 (decreased by 53%), c-MYC (63%), c-JUN (92%) and MET (96%) proteins. Likewise, the PI3K/AKT/mTOR pathway was significantly inhibited by 1% Naltrexone HCl in XemaTop™, suggesting protein synthesis was affected. The production of IL-6 was inhibited by 70% in drug-treated tissues. These results suggest that the compounded drug is efficacious in down-regulating molecular markers associated with the pathogenesis of psoriasis. Low-dose Naltrexone in XemaTop™ was stable within 180 days when stored under refrigerated or ambient conditions. These results provide a basis for a clinical evaluation of 1% Naltrexone HCl in XemaTop™ in psoriasis patients.Keywords
This publication has 25 references indexed in Scilit:
- The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic painClinical Rheumatology, 2014
- Activation of phosphatidylinositol 3-kinase/Akt-mammalian target of Rapamycin signaling pathway in the hippocampus is essential for the acquisition of morphine-induced place preference in ratsNeuroscience, 2010
- Antipruritic treatment with systemic μ-opioid receptor antagonists: A reviewJournal of the American Academy of Dermatology, 2010
- Topical Clobetasol Propionate in the Treatment of PsoriasisAmerican Journal of Clinical Dermatology, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesisThe International Journal of Biochemistry & Cell Biology, 2009
- Secreted antagonists of the Wnt signalling pathwayJournal of Cell Science, 2003
- lnterleukin-6 and the SkinInternational Archives of Allergy and Immunology, 1996
- Cell Kinetic Basis for Pathophysiology of PsoriasisJournal of Investigative Dermatology, 1985
- Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferationBritish Journal of Dermatology, 1985